Xenon Pharmaceuticals Inc
XENE
Market Cap$3.31B
Close$
$2.06
94.7% downside
Current Fair Value
94.7% downsideOvervalued by 94.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.31 Billion |
|---|---|
| Enterprise Value | $3.18 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.5 |
| Beta | 0.59 |
| Outstanding Shares | 75,468,883 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -20.17 |
|---|---|
| PEG | -91.51 |
| Price to Sales | - |
| Price to Book Ratio | 3.51 |
| Enterprise Value to Revenue | 591.56 |
| Enterprise Value to EBIT | -13.3 |
| Enterprise Value to Net Income | -16 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Xenon Pharmaceuticals Inc
CEO: Simon Pimstone